A comparison of hepatitis B virus infection in HIV-infected and HIV-uninfected participants enrolled in a multinational clinical trial: HPTN 052

dc.creatorGreer, Amy E.
dc.creatorOu, San-San
dc.creatorWilson, Ethan
dc.creatorPiwowar-Manning, Estelle
dc.creatorForman, Michael S.
dc.creatorMcCauley, Marybeth
dc.creatorGamble, Theresa
dc.creatorRuangyuttikarn, Cholticha
dc.creatorHosseinipour, Mina C.
dc.creatorKumarasamy, Nagalingeswaran
dc.creatorNyirenda, Mulinda
dc.creatorGrinsztejn, Beatriz
dc.creatorPilotto, Jose Henrique
dc.creatorKosashunhanan, Natthapol
dc.creatorGonçalves de Melo, Marineide
dc.creatorMakhema, Joseph
dc.creatorAkelo, Victor
dc.creatorPanchia, Ravindre
dc.creatorBadal-Faesen, Sharlaa
dc.creatorChen, Ying Q.
dc.creatorCohen, Myron S.
dc.creatorEshleman, Susan H.
dc.creatorThio, Chloe L.
dc.creatorValsamakis, Alexandra
dc.date2019-08-28T14:22:04Z
dc.date2019-08-28T14:22:04Z
dc.date2017
dc.date.accessioned2023-09-26T22:54:26Z
dc.date.available2023-09-26T22:54:26Z
dc.identifier10.1097/QAI.0000000000001511
dc.identifierGREER, Amy E. et al. A comparison of hepatitis B virus infection in HIV-infected and HIV-uninfected participants enrolled in a multi-national clinical trial: HPTN 052. Journal of Acquired Immune Deficiency Syndromes, v. 76, n. 4, p. 1-16, Dec. 2017.
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/35158
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8884607
dc.descriptionObjective — Data comparing hepatitis B virus (HBV) infection in HIV-infected [HIV(+)], and HIV-uninfected [HIV(−)] individuals recruited into the same study are limited. HBV infection status and chronic hepatitis B (cHB) were characterized in a multi-national clinical trial: HIV Prevention Trials Network (HPTN 052). Method — HBV infection status at enrollment was compared between HIV(+) (N=1241) and HIV(−) (N=1232) from seven HBV-endemic countries. Hepatitis B e antigen (HBeAg) and plasma HBV DNA were determined in cHB. Median CD4, median plasma HIV RNA, and prevalence of transaminase elevation were compared in HIV(+) with and without cHB. Significance was assessed with Chi-square, Fisher’s exact, and median tests. Results — Among all participants, 33.6% had HBV exposure without cHB (8.9% isolated HBV core antibody, “HBcAb”; 24.7% HBcAb and anti-HB surface antibody positive, “recovered”), 4.3% had cHB, 8.9% were vaccinated, and 53.5% were uninfected. Data were similar among HIV(+) and HIV(−) except for isolated HBV core antibody (HBcAb), which was more prevalent in HIV(+) than HIV(−) [10.1% vs. 7.7%, P=0.046]. Median HBV DNA trended higher in HIV(+) than in HIV(−). In HIV(+) with cHB versus those without cHB, transaminase elevations were more prevalent (ALT ≤ Grade 2, 12% vs. 5.2%, P=0.037; AST ≤ Grade 2, 26% vs. 6.0%, P<0.001), CD4 trended lower, and HIV RNA was similar. Conclusions — HBV infection status did not differ by HIV infection status. HIV co-infection was associated with isolated HBcAb and a trend of increased HBV DNA. In HIV, cHB was associated with mild transaminase elevations and a trend toward lower CD4.
dc.formatapplication/pdf
dc.languageeng
dc.publisherLippincott, Williams & Wilkins
dc.relationhttps://www.arca.fiocruz.br/handle/icict/25438
dc.rightsopen access
dc.subjectHIV
dc.subjectHIV
dc.subjectHBV
dc.subjectCD4 cell count
dc.subjectChronic HBV infection
dc.subjectEndemic HBV
dc.subjectPrevalence of HBV infection
dc.subjectHIV-HBV co-infection
dc.titleA comparison of hepatitis B virus infection in HIV-infected and HIV-uninfected participants enrolled in a multinational clinical trial: HPTN 052
dc.typePreprint


Este ítem pertenece a la siguiente institución